Research Article
Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis
Table 1
Main characteristics of the included studies.
| | First author | Year | Region | Age, median (range) | Cancer type | Study design | Time of Recruitment | Follow-up (months) | Number of patients | Stage range | Cutoff value | Therapy | Outcome | statistical mode | NOS
score |
| | Li | 2016 | China | 54(19-79) | HCC | Retrospective | 2010.1-2014.12 | 15(3-73) | 119 | BCLC(BC) | 221 | TACE/Chemotherapy | OS/PFS | M | 7 | | Zhang | 2015 | China | NA | HCC | Retrospective | 2008.1-2012.6 | 41(1-86) | 683 | TNM(I-IV) | 188 | curative resection | OS/DFS | M | 7 | | Kohles | 2012 | Germany | 66.7(mean) | HCC | Retrospective | 2006-2008 | Max:24 | 38 | NA | 201 | TACE | OS | M | 6 | | Wu | 2016 | China | 48(17-81) | HCC | Retrospective | 2007.6-2013.3 | 42(2-99) | 469 | BCLC(0ABC) | 203.5 | curative resection | OS/RFS | M | 7 | | Falopp | 2014 | Italy | NA | HCC | Retrospective | 2008-2012 | Max:50 | 78 | BCLC(BC) | 407 | sorafenib | OS/PFS | M | 7 | | Jun | 2013 | Korea | 59.1(32-87) | HCC | Retrospective | 2005.1-2012.12 | 27.3(0-115) | 743 | TNM(I-IV) | 450 | surgical resection/PEIT/RFA/TACE/HAIC/
RT/BSC | OS | M | 6 | | Wang | 2015 | China | 54±12.1 | HCC | Retrospective | 2007.5-2011.5 | 39.4(3-97.6) | 200 | BCLC(0ABC)/TNM(I-IV)/
Edmonson-Steiner grade (I-IV) | 206 | curative resection | RFS | M | 6 | | Chen | 2010 | China | 53.15±11.63 | HCC | Retrospective | 2001.1-2007.12 | Max:2500 days | 37 | NA | 200 | surgery after admission | OS | M | 6 | | Scartozzi | 2012 | Italy | NA | HCC | Retrospective | 2002-2010 | Max:30 | 114 | BCLC(ABC) | 450 | TACE | OS/PFS | U | 7 | | suzuki | 2015 | Japan | 68(37-82) | HCC | Retrospective | 2000.2-2010.10 | Max:80 | 95 | NA | 230 | TAI | OS | M | 6 |
|
|
Notes: NOS: Newcastle-Ottawa Scale; NA: not available; HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; TNM: Tumor Node Metastasis; Max: maximum; TACE: transcatheter arterial chemoembolization; RFA: radiofrequency ablation; PEIT: percutaneous ethanol injection therapy; HAIC: hepatic artery infusion chemotherapy; RT: radiation therapy; BSC: best supportive care; TAI: transcatheter arterial infusion chemotherapy; OS: overall survival; RFS: recurrence-free survival; DFS: disease free survival; PFS: progression-free survival; M: multivariate analysis; U: univariate analysis.
|
